Skip to main content
Anbio Biotechnology logo

Anbio Biotechnology — Investor Relations & Filings

Ticker · NNNN ISIN · KYG0367B1059 LEI · 9845006F57813BI98445 US Manufacturing
Open in API
Filings indexed 35 across all filing types
Latest filing 2026-05-19 Declaration of Voting R…
Country KY Cayman Islands
Listing US NNNN

About Anbio Biotechnology

https://anbiobiotechnology.com/

Anbio Biotechnology is a medical device company specializing in the development and provision of in-vitro diagnostic (IVD) solutions. The company's portfolio includes a diverse range of diagnostic instruments and assays for laboratory, point-of-care (POCT), and over-the-counter (OTC) applications. Its products are designed to detect biomarkers across numerous medical fields, such as infectious diseases, cancer, cardiovascular diseases, inflammation, and endocrine disorders. Anbio utilizes five core technology platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR), and Loop-mediated Isothermal Amplification (LAMP). The company focuses on advancing medical technology by creating personalized and decentralized diagnostic tools to enhance patient care and outcomes globally.

Recent filings

Filing Released Lang Actions
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is a Form 6-K filed by a foreign private issuer reporting the official results of its Class A Meeting and Extraordinary General Meeting, including detailed vote counts (for, against, abstain) on various share capital and governance proposals. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-19 English
6-K - Anbio Biotechnology (0001982708) (Filer)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Anbio Biotechnology, pursuant to the SEC rules. It contains a Notice of Meetings of Shareholders, Proxy Statement, and Proxy Cards related to an extraordinary general meeting of shareholders. The document is relatively short (2277 characters) and primarily serves to provide meeting materials and proxy information. It does not contain financial statements or detailed financial analysis. The presence of proxy materials and meeting notices indicates it is related to shareholder meeting information rather than a full annual report or earnings release. Therefore, the document fits best under Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
20-F/A - Anbio Biotechnology (0001982708) (Filer)
Annual Report FY 2025
2026-04-09 English
20-F - Anbio Biotechnology (0001982708) (Filer)
Annual Report FY 2025
2026-04-07 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Anbio Biotechnology, reporting a change in the company's certifying accountant. It details the dismissal of the previous auditor and appointment of a new auditor, including statements about disagreements and consultations. The document does not contain financial statements or substantive financial data but is an announcement of a change in auditor. It is not an annual report, audit report, or interim report itself, but a regulatory filing informing the SEC and investors of this change. The document length is 4770 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-02-17 English
FORM 6-K
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Anbio Biotechnology, with the SEC. It announces the appointment of a new director, Michael Zhang, replacing Kenneth Li, and provides biographical details and committee assignments. The document includes the director offer letter as an exhibit and is signed by the CEO. There is no financial data or report content; it is an announcement of a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document length is 4096 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2026-01-26 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.